Introduction
============

Colorectal cancer remains one of the leading causes of cancer death worldwide and in Taiwan. The 5-year survival rates are approximately 90% for early stage colorectal cancer patients, but decreasing to less than 10% in patients with distant metastases [@B1]. In addition, about 25 to 40 percent of patients who undergo curative surgery for localized colorectal cancer eventually recur and develop metastases, but current clinicopathologic indicators do not predict the outcomes [@B2]. Therefore, there is a need to identify and select appropriate adjuvant therapy for patients at high risk in development of metastases.

Cancer metastasis is a complex multifactorial and multistep process, involving invasion of stroma, intravasation into the circulation from the primary site, extravasation at the secondary site, and outgrowth of new tumors. These processes require degradation of the extracellular matrix components by proteolytic enzymes. The most important proteinases capable of creating a pathway for tumor cell migration are the matrix metalloproteinases (MMPs). One particular group of MMPs, the gelatinases A and B also known as MMP2 and MMP9, play a crucial role during colorectal cancer invasion and metastasis. The levels of gene expression and enzymatic activity of MMP2 and MMP9 were higher in tumors compared with normal mucosa, and their overexpression is associated with a poor prognosis in colorectal cancer patients [@B3]-[@B5].

Lots of molecular epidemiological studies have focused on the associations between *MMP* polymorphisms and the risk of colorectal cancer [@B6]-[@B10], but little is known about their relationship to cancer prognosis. Thus, the aim of the present study was to assess the association of *MMP2* and *MMP9* single-nucleotide polymorphisms (SNPs) with distant metastasis-free and overall survival in a cohort of 282 colorectal cancer patients.

Materials and Methods
=====================

Patient recruitment and data collection
---------------------------------------

Two hundred and eighty-two colorectal cancer patients were retrospectively examined the records in the China Medical University Hospital, Taiwan between 2001 and 2007. All cases were histopathologically confirmed, and the clinical data and outcomes were obtained from patients\' clinical records and pathological reports. Among patients receiving curative surgery (stage I-III, n = 233), distant metastasis-free survival was defined as the time from surgery to the date of distant metastases or when censored at the latest date. Overall survival was defined as the time from diagnosis (n = 282) to the date of death from any cause or when censored at the latest date if patients were still alive. The survival data were updated most recently in 2010. This study was approved by the Institutional Review Board of the China Medical University Hospital and written informed consent was obtained from all patients.

SNP selection and genotyping
----------------------------

Four SNPs in *MMP2* and *MMP9* were selected based on the evidence of association with cancers [@B11]-[@B13]. The *MMP2* rs243866 (-1575) located immediately 5\' to the potential estrogen receptor binding site and functioned as an enhancer [@B14]. The *MMP2* rs2285053 (-735) have been shown to affect *MMP2* expression by lowering transcriptional activity [@B15], [@B16]. Several studies have evaluated the association of *MMP9* rs3787268 and rs17577 with cancer susceptibility, such as breast [@B12], prostate [@B13], and colorectal [@B17] cancers, but their clinical impact on cancer prognosis and outcomes has not been well evaluated. The *MMP9* rs17577 (rs2274756, Arg668Gln) is in the hemopexin-like domain and probably functions in substrate binding, since removal of this domain disables the cleavage of collagen [@B18].

Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) and stored at -80°C until the time of study. Genotyping was performed as described previously [@B19]-[@B24] using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry technology at the National Center for Genome Medicine, Academia Sinica, Taiwan. The SNPs were all in Hardy-Weinberg equilibrium (*P* \> 0.05), and the average genotype call rate for these SNPs was 99.5%.

Statistical analysis
--------------------

Patient clinicopathologic characteristics were summarized as number and percentage of patients or median and interquartile range (IQR) of values. Age was dichotomized at the median value within the cohort. Carcinoembryonic antigen (CEA) level was dichotomized at 5 μg/L because of its correlation with an increasing stage of the colorectal cancer [@B25]. The associations of 4 *MMP* SNPs and clinical characteristics with distant metastasis-free and overall survival were assessed using Cox proportional hazards model and Kaplan-Meier analysis with log-rank test. We tested different genetic models, dominant, recessive, and additive models for each SNP. The model with the most significant *P* value was considered the best-fitting model. Higher order SNP-SNP interactions were evaluated using survival tree analysis by STREE software (<http://c2s2.yale.edu/software/stree/>), which uses recursive partitioning to identify subgroups of individuals with similar risk [@B26]. Patients were then categorized into low-, medium-, and high-risk groups based on the survival tree analysis. Multivariate analyses to determine the interdependency of genotypes and other known prognostic factors, such as age at diagnosis, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement, were carried out using Cox proportional hazards model. Statistical Package for the Social Sciences software version 19.0.0 (IBM, Armonk, NY) was used for other statistical analyses. A two-sided *P* value of ≤ 0.05 was considered statistically significant.

Results
=======

DNA was extracted for analysis from the blood samples of 282 colorectal cancer patients. Of the 233 patients receiving curative surgery (stage I-III), 30 (12.9%) developed distant metastasis during the median follow-up of 54.5 months (Table [1](#T1){ref-type="table"}). Among the 282 patients diagnosed with colorectal cancer, 92 (32.6%) died after a median follow-up of 50.0 months. Stage, lymphovascular invasion, and lymph node involvement were significantly associated with both distant metastasis-free and overall survival. Gender, CEA levels, tumor differentiation, and perineural invasion were only associated with overall survival, and age was only associated with distant metastasis-free survival.

We assessed the association of 4 *MMP* SNPs with distant metastasis-free and overall survival under dominant, recessive, and additive genetic models (Table [2](#T2){ref-type="table"}). We defined the model with the most significant *P* value as the best model. Patients carrying AA genotype, minor allele homozygote, of *MMP2* rs243866 had a significantly increased risk of developing distant metastasis following curative surgery compared with those with at least one G, major allele \[hazard ratio (HR): 6.32, 95% confidence interval (CI): 1.50-26.7, *P* = 0.012\]. We did not observe statistically significant relations between other *MMP* SNPs and distant metastasis-free and overall survival. We also found no association between the 4 *MMP* SNPs with clinicopathologic features listed in Table [1](#T1){ref-type="table"}, except for the *MMP2* rs2285053 showing a significant association with CEA levels (*P* = 0.030, data not shown).

We noted that the association of *MMP2* rs243866 with distant metastasis-free survival was based on a very low number of minor allele homozygous patients (n = 4) and required more cautious interpretation. Thus, we further used survival tree analysis to explored higher order SNP-SNP interactions to evaluate whether the interactions among *MMP* SNPs could determine the clinical outcomes. The tree structure resulted in 3 terminal nodes, ranging from low, medium, and high risk in developing distant metastasis after curative surgery (Fig. [1](#F1){ref-type="fig"}A). When using low risk node 4 as the reference group (wild-type homozygous genotypes of *MMP2* rs2285053 and *MMP2* rs243866), the HR was 2.79 (95% CI, 1.04-7.53, Table [3](#T3){ref-type="table"}) for medium risk node 1, and 3.70 (95% CI, 1.18-11.7) for high risk node 3 (*P*~trend~ = 0.017). The time to develop distant metastasis decreased as the increase in risk classification by *MMP2* SNPs (log-rank *P* = 0.016, Fig. [1](#F1){ref-type="fig"}B). However, no genetic interaction was observed for overall survival.

To adjust for potential confounding between the genetic interactions of *MMP2* SNPs and distant metastasis-free survival, a Cox proportional hazards model was constructed. The multivariable model was adjusted for age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement as covariates. The genetic interaction profile between *MMP2* rs2285053 and *MMP2* rs243866 remained significantly associated with distant metastasis-free survival (HR: 1.77, 95% CI: 1.00-3.15, adjusted *P*~trend~ = 0.050, Table [3](#T3){ref-type="table"}).

Discussion
==========

The expression levels of MMP2 and MMP9 have been shown to be correlated with colorectal cancer initiation, progression, angiogenesis, metastasis, and recurrence [@B27]-[@B29]. Many studies have also proved that *MMP* SNPs have associations with cancer susceptibility including colorectal cancer [@B6]-[@B10], but little is known about their prognostic significance. In the present study, we found *MMP2* rs243866 and a higher-order genetic interaction profile between *MMP2* rs243866 and *MMP2* rs2285053 were significantly associated with distant metastasis-free survival in colorectal cancer patients receiving curative surgery. Moreover, the association between the genetic interaction profile and distant metastasis-free survival persisted despite controlling for known clinical prognostic factors, including age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement.

The *MMP2* rs2285053 (-735) C to T transition has been previously reported to affect *MMP2* transcription due to the ablation of specificity protein (Sp) 1 transcription factor binding [@B15], [@B16]. Similarly, it has also been reported that the *MMP2* rs243866 G allele located in a potential estrogen receptor binding site and functioned as an enhancer, whereas the A allele showed reduced transcriptional activity in estrogen receptor-positive breast cancer cell line MCF-7 cells [@B14]. In this study, we identified that colorectal cancer patients carrying AA genotype at *MMP2* rs243866 had a 6.32-fold higher risk of developing distant metastasis after curative surgery compared with those with at least one G. These results are in contrast to the previous notion that high expression levels of MMP2 in rs243866 GG genotype carriers are associated with an invasive phenotype of cancer. However, our observation coincides with a previous study showing that the *MMP2* rs243866 GG genotype was associated with a reduced risk of colorectal cancer [@B30]. There are several possible explanations for this discrepancy. First, the *MMP2* rs243866 was also reported to be not functional when tested within estrogen receptor-negative cells [@B15], suggesting that the functional effect varies depending on cell type. Second, it is important to consider that the activity of MMP2 is influenced not only by the level of its expression but also by its activators and inhibitors. Finally, although the original notion that MMPs act as metastasis-promoting enzymes by clearing a pathway for cancer cell invasion, more recent evidence indicates that some MMPs have anti-metastatic functions [@B31]. Mounting evidence demonstrates that MMPs not only regulate the metastatic potential of cancer cells but also regulate cell proliferation, apoptosis, epithelial-mesenchymal transition, angiogenesis, and inflammatory response by targeting non-matrix proteins such as growth factors and their receptors, chemokines, and adhesive molecules. The complexity of the pro- and anti-tumorigenic and -metastatic functions might at least partly explain why MMP inhibitors failed in clinical trials. Together, these observations indicate that the balance between the pro- and anti-metastatic actions of MMPs is critical in determining their overall impact on cancer progression, and this paradox needs further investigation.

There are several strengths in this study. The patients analyzed in this study were enrolled from a single hospital, so patient characteristics and treatments are highly homogenous. We chose to investigate common *MMP* SNPs for which an association with cancer is biologically plausible and has been previously reported. However, some limitations in this study should also be considered when interpreting our results. The sample size is small and we had relatively few cases with distant metastasis. In addition, our homogeneous Chinese Han population might make our findings less generalizable to other ethnic groups. Additional studies in other populations are necessary to validate our findings.

In conclusion, our findings suggest that genetic variants in *MMP2* might modulate colorectal cancer metastasis. We are able to identify subgroups of patients with different genetic profiles at *MMP2* and predict their distant metastasis-free survival after curative surgery.
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![Potential higher order SNP-SNP interactions between *MMP2* gene polymorphisms. (A) Survival tree analysis identifies the interactions between *MMP2* gene polymorphisms. (B) Kaplan-Meier curves of distant metastasis-free survival based on the survival tree analysis. Numbers in parentheses indicate the number of patients.](ijmsv10p1022g01){#F1}

###### 

Demographic and clinical characteristics of colorectal cancer patients.

  Characteristics           Distant metastasis-free survival   Overall survival                                                                            
  ------------------------- ---------------------------------- ------------------ ------------------ ---------------- ------------ ---- ------------------ -------------
  All patients              233                                30                                                     282          92                      
  Age, years                                                                                                                                               
  Median (IQR)              66 (56-73)                                                                                65 (54-73)                           
  \<65                      106 (45.5)                         19                 1.00                                133 (47.2)   42   1.00               
  ≥65                       127 (54.5)                         11                 0.48 (0.23-1.00)   **0.049**        149 (52.8)   50   1.09 (0.72-1.64)   0.692
  Gender                                                                                                                                                   
  Male                      119 (51.1)                         17                 1.00                                148 (52.5)   57   1.00               
  Female                    114 (48.9)                         13                 0.78 (0.38-1.61)   0.508            134 (47.5)   35   0.65 (0.43-0.99)   **0.045**
  CEA, μg/L                                                                                                                                                
  Median (IQR)              3.5 (1.7-10.2)                                                           4.4 (2.0-14.9)                                        
  \<5                       129 (59.7)                         14                 1.00                                136 (52.3)   23   1.00               
  ≥5                        87 (40.3)                          15                 1.61 (0.78-3.34)   0.198            124 (47.7)   58   3.35 (2.07-5.44)   **\<0.001**
  Differentiation                                                                                                                                          
  Well                      43 (20.0)                          5                  1.00                                51 (19.4)    11   1.00               
  Moderate                  153 (70.8)                         17                 0.95 (0.35-2.56)   0.912            185 (70.3)   62   1.64 (0.86-3.12)   0.131
  Poor                      19 (9.2)                           6                  3.17 (0.97-10.4)   0.057            27 (10.3)    15   3.59 (1.65-7.83)   **0.001**
  Stage†                                                                                                                                                   
  I-II                      150 (64.7)                         12                 1.00                                \-                                   
  III                       82 (35.3)                          18                 2.92 (1.41-6.06)   **0.004**        \-                                   
  I-III                     \-                                                                                        232 (82.6)   54   1.00               
  IV                        \-                                                                                        49 (17.4)    38   5.19 (3.40-7.92)   **\<0.001**
  Lymphovascular invasion                                                                                                                                  
  Negative                  179 (76.8)                         14                 1.00                                201 (71.3)   48   1.00               
  Positive                  54 (23.2)                          16                 4.13 (2.02-8.47)   **\<0.001**      81 (28.7)    44   2.78 (1.84-4.19)   **\<0.001**
  Perineural invasion                                                                                                                                      
  Negative                  202 (86.7)                         23                 1.00                                234 (83.0)   65   1.00               
  Positive                  31 (13.3)                          7                  2.01 (0.86-4.67)   0.107            48 (17.0)    27   2.39 (1.53-3.75)   **\<0.001**
  Lymph node involvement                                                                                                                                   
  Negative                  143 (64.1)                         10                 1.00                                154 (56.8)   33   1.00               
  Positive                  80 (35.9)                          17                 3.24 (1.48-7.08)   **0.003**        117 (43.2)   56   2.76 (1.79-4.24)   **\<0.001**

Abbreviations: HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; IQR, interquartile range. \*Column subtotals do not sum to n of patients and n of events due to missing data.†According to the American Joint Committee on Cancer - Cancer Staging Manual (version 6.0). *P* ≤ 0.05 are in boldface.

###### 

Association of *MMP* gene polymorphisms with distant metastasis-free survival and overall survival.

  Gene     SNP ID      Position         Location             Allele   Genotype Distribution\*   Best-fitting genetic models                                                                 
  -------- ----------- ---------------- -------------------- -------- ------------------------- ----------------------------- ------------------ ----------- ----------- ------------------ -------
  *MMP2*   rs243866    Chr16:55511537   5\' upstream         G\>A     223/53/4                  Recessive                     6.32 (1.50-26.7)   **0.012**   Additive    0.91 (0.78-1.45)   0.696
  *MMP2*   rs2285053   Chr16:55512377   5\' upstream         C\>T     144/121/16                Dominant                      1.59 (0.77-3.30)   0.213       Recessive   0.79 (0.29-2.16)   0.646
  *MMP9*   rs3787268   Chr20:44641731   Intron 8             G\>A     93/138/49                 Recessive                     1.55 (0.66-3.60)   0.314       Additive    1.18 (0.88-1.59)   0.260
  *MMP9*   rs17577     Chr20:44643111   Exon 12, Arg668Gln   G\>A     213/64/4                  Recessive                     2.34 (0.32-17.1)   0.404       Additive    0.76 (0.47-1.22)   0.255

Abbreviations: SNP, single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; MMP, matrix metalloproteinase. \*The number represents major allele homozygotes, heterozygotes, and minor allele homozygotes, respectively. *P* ≤ 0.05 are in boldface.

###### 

Cox proportional hazards analysis of *MMP2* genetic interaction profiles and distant metastasis-free survival.

  Variables                   n (%)        n of events   Univariate analysis   Multivariate analysis\*                      
  --------------------------- ------------ ------------- --------------------- ------------------------- ------------------ -----------
  *MMP2* gene polymorphisms                                                                                                 
  Low risk                    85 (36.5)    5             1.00                                            1.00               
  Medium risk                 113 (48.5)   18            2.79 (1.04-7.53)      **0.042**                 3.73 (1.18-11.8)   **0.025**
  High risk                   35 (15.0)    7             3.70 (1.18-11.7)      **0.025**                 3.37 (0.86-13.2)   0.082
  Trend                                                  1.87 (1.12-3.12)      **0.017**                 1.77 (1.00-3.15)   **0.050**

Abbreviations: HR, hazard ratio; CI, confidence interval; MMP, matrix metalloproteinase. \*Age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, lymph node involvement, and genetic risk classification by *MMP2* polymorphisms were included in the multivariate analysis. *P* ≤ 0.05 are in boldface.
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